Valuation: Valneva SE

Market Cap 409M 468M 377M 348M 655M 45.06B 670M 4.51B 1.77B 22.07B 1.76B 1.72B 75.97B P/E 2026 *
-5.87x
P/E 2027 * 5.67x
Enterprise Value 537M 614M 495M 457M 861M 59.16B 880M 5.92B 2.33B 28.98B 2.31B 2.26B 99.75B EV / Sales 2026 *
3.54x
EV / Sales 2027 * 1.59x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day-38.30%
1 week+15.92%
Current month+14.71%
1 month+14.02%
3 months+0.26%
6 months-39.69%
Current year-30.05%
1 week 2.1
Extreme 2.098
2.59
1 month 2.1
Extreme 2.098
2.59
Current year 2.1
Extreme 2.098
5.15
1 year 2.1
Extreme 2.098
5.42
3 years 1.72
Extreme 1.717
7.14
5 years 1.72
Extreme 1.717
29.54
10 years 1.72
Extreme 1.717
29.54
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-38.30%+15.92% - - 468M
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average -3.66%+0.04%+223.08%+179.48% 22.91B
Weighted average by Cap. +0.15%+0.36%+171.43%+187.42%

Financials

2026 *2027 *
Net sales 152M 174M 140M 129M 243M 16.73B 249M 1.67B 659M 8.19B 652M 638M 28.21B 294M 336M 271M 250M 471M 32.4B 482M 3.24B 1.28B 15.87B 1.26B 1.24B 54.63B
Net income -66.01M -75.54M -60.92M -56.15M -106M -7.27B -108M -728M -286M -3.56B -284M -277M -12.26B 70.5M 80.67M 65.06M 59.97M 113M 7.77B 116M 778M 306M 3.8B 303M 296M 13.1B
Net Debt 128M 146M 118M 109M 205M 14.11B 210M 1.41B 555M 6.91B 550M 538M 23.78B 60.02M 68.68M 55.38M 51.05M 96.22M 6.61B 98.35M 662M 260M 3.24B 258M 252M 11.15B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
26-07-17 €2.152 -1.14% 20,185
26-07-16 €2.177 -0.80% 23,994
26-07-15 €2.194 +0.10% 11,666
26-07-14 €2.192 -4.94% 23,371
26-07-13 €2.306 +3.11% 12,482
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.156EUR
Average target price
5.233EUR
Spread / Average Target
+142.73%

Quarterly revenue - Rate of surprise